Aminobisphosphonate — once-monthly oral or once-quarterly IV dosing for postmenopausal osteoporosis. Lower vertebral-fracture-only evidence vs alendronate / risedronate (no demonstrated hip-fracture reduction).
Half-Life & Elimination Curve (PO: 10d · IV: 10d)
Plasma (PO)t½ Decay (10d)
0×t½0h100%(9.87 µg/L)
1×t½10d50%(4.94 µg/L)
2×t½20d25%(2.47 µg/L)
3×t½30d12.5%(1.23 µg/L)
4×t½40d6.3%(0.617 µg/L)
5×t½50d3.1%(0.309 µg/L)
Elimination t½10d (PO)
Rate Constant (ke)0.00289 h⁻¹
Time to Peak (Tmax)4.43h
Est. Peak (Cmax)9.87 µg/L
Clearance (CL)0.26 L/h
97% Washout (5×t½)50d
Dosing Guidelines
Oral (PO): Typical 150 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 0.6% · Volume of Distribution (Vd): 90 L · Absorption (ka): 1.4 h⁻¹ (t½ka ≈ 30m) [PMID 24756462]
Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 90 L [PMID 24756462]
Pathways It Modulates
Bone remodeling (inhibitor) — osteoclast farnesyl-PP synthase